Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells

Molecular Cancer Therapeutics

Volumn 8, Issue 9, 2009, Pages 2509-2516

  Mak, Duncan H ^a   Schober, Wendy D ^a   Chen, Wenjing ^a   Konopleva, Marina ^a   Cortes, Jorge ^a   Kantarjian, Hagop M ^a   Andreeff, Michael ^a   Carter, Bing Z ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CD34 ANTIGEN; DASATINIB; IMATINIB; NILOTINIB; PROTEIN MCL 1; TRIPTOLIDE; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CANCER CELL DESTRUCTION; CANCER PATIENT; CANCER RESISTANCE; CANCER STEM CELL; CELL LEVEL; CELL VIABILITY; CHEMOSENSITIVITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG RESPONSE; GENE MUTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BLAST CRISIS; BLOTTING, WESTERN; CELL LINE, TUMOR; DITERPENES; EPOXY COMPOUNDS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHENANTHRENES; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 70349515363     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0386     Document Type: Article

References (47)

1. Jandl JH. Blood: pathophysiology. Boston: Blackwell Scientific Publication; 1991.
2. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A 1990;87:6649-6653 (Pubitemid 20351538)
3. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-830 (Pubitemid 20078558)
4. Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 1990;9:1069-1078 (Pubitemid 20110570)
5. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547-3553 (Pubitemid 34534521)
6. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-3539 (Pubitemid 34534519)
7. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880 (Pubitemid 32743979)
8. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95:1758-1766 (Pubitemid 30120840)
9. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498-3505 (Pubitemid 30428483)
10. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472-3475 (Pubitemid 34525335)
11. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002;359:487-491 (Pubitemid 34164296)
12. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002;100:1014-1018 (Pubitemid 34832631)
13. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-125 (Pubitemid 41039112)
14. Nowicki MO, Falinski R, Koptyra M, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004;104:3746-3753 (Pubitemid 39564453)
15. Bartholomeusz GA, Talpaz M, Kapuria V, et al. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 2007;109:3470-3478 (Pubitemid 46572537)
16. Shiotsu Y, Soga S, Akinaga S. Heat shock protein 90-antagonist destabilizes Bcr-Abl/HSP90 chaperone complex. Leuk Lymphoma 2002;43:961-968 (Pubitemid 34460877)
17. Cobaleda C, Sanchez-Garcia I. In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment. Blood 2000;95:731-737
18. Eaves C, Cashman J, Eaves A. Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia. Leuk Res 1998;22:1085-1096 (Pubitemid 29002983)
19. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999;94:2056-2064 (Pubitemid 29430422)
20. Elrick LJ, Jorgensen HG, Mountford JC, Holyoake TL. Punish the parent not the progeny. Blood 2005;105:1862-1866
21. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-325
22. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction. Blood 2006;107:4532-4539 (Pubitemid 43801382)
23. Shamon LA, Pezzuto JM, Graves JM, et al. Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii. Cancer Lett 1997;112:113-117
24. Yang S, Chen J, Guo Z, et al. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2003;2:65-72.
25. Kiviharju TM, Lecane PS, Sellers RG, Peehl DM. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 2002;8:2666-2674
26. Yang Y, Liu Z, Tolosa E, Yang J, Li L. Triptolide induces apoptotic death of T lymphocyte. Immunopharmacology 1998;40:139-149 (Pubitemid 28439168)
27. Carter BZ, Mak DH, Schober WD, et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006;108:630-637 (Pubitemid 44061364)
28. Aichberger KJ, Mayerhofer M, Krauth MT, et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005;105:3303-3311 (Pubitemid 40504353)
29. Shi X, Jin Y, Cheng C, et al. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res 2009;15:1686-1697
30. Beran M, Pisa P, O'Brien S, et al. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res 1993;53:3603-3610 (Pubitemid 23229644)
31. Ricci C, Scappini B, Divoky V, et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res 2002;62:5995-5998 (Pubitemid 35244441)
32. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002;99:3792-3800 (Pubitemid 34534553)
33. Itoh K, Tezuka H, Sakoda H, et al. Reproducible establishment of hemopoietic supportive stromal cell lines from murine bone marrow. Exp Hematol 1989;17:145-153 (Pubitemid 19056039)
34. - progenitor cells in long-term cultures and semisolid assays. Blood 1993;81:2916-2924
35. Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M. Stroma cells prevent apoptosis of AML cells by upregulation of anti-apoptotic proteins. Leukemia 2002;16:1713-1724 (Pubitemid 35050102)
36. Carter BZ, Milella M, Altieri DC, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood 2001;97:2784-2790
37. Lou YJ, Jin J. Triptolide down-regulates bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells. Leuk Lymphoma 2004;45:373-376 (Pubitemid 38181443)
38. Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006;3:448-457 (Pubitemid 44203817)
39. Fidler JM, Li K, Chung C, et al. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol Cancer Ther 2003;2:855-862
40. Lipsky PE, Tao XL. A potential new treatment for rheumatoid arthritis: thunder god vine. Semin Arthritis Rheum 1997;26:713-723 (Pubitemid 27190960)
41. Wu SX, Guo NR. Clinical observation on effect of triptolide tablet in treating patients with psoriasis vulgaris. Chin J Integr Med 2005;11:147-148
42. Harousseau JLH, Dombret HD, Pigneux AP, Michallet MM, Brandely MB. Phase I study of F60008, a triptolide derivative, in patients with refractory or relapsing acute leukemias [abstract]. 13th Congress of the European Hematology Association (EHA); 2008.
43. Dexter TM. Regulation of hemopoietic cell growth and development: experimental and clinical studies. Leukemia 1989;7:469-474 (Pubitemid 19160982)
44. Dorshkind K. Regulation of hemopoiesis by bone marrow stromal cells and their products. Annu Rev Immunol 1990;8:111-137 (Pubitemid 20135623)
45. Asosingh K, Gunthert U, Bakkus MH, et al. In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Res 2000;60:3096-3104
46. Shimakura Y, Kawada H, Ando K, et al. Murine stromal cell line HESS-5 maintains reconstituting ability of ex vivo-generated hematopoietic stem cells from human bone marrow and cytokine-mobilized peripheral blood. Stem Cells 2000;18:183-189 (Pubitemid 30341666)
47. - cells and stroma induces a soluble activity that specifically increases primitive hematopoietic cell production. Exp Hematol 1999;27:734-741